Clinical Trials Logo

Filter by:
NCT ID: NCT05786820 Recruiting - Periodontitis Clinical Trials

Impact of Pycnogenol® on Gingival Inflammation

PINEGIN
Start date: March 17, 2022
Phase: N/A
Study type: Interventional

This randomized, double-blind, placebo-controlled 2-arm, parallel group clinical trial is designed to evaluate the impact of the regular consumption of a polyphenol-containing Maritime Pine (Pinus pinaster) bark extract (Pycnogenol®) on clinical signs of gingival inflammation in a cohort of periodontal aftercare patients

NCT ID: NCT05786196 Recruiting - Clinical trials for Primary Open Angle Glaucoma

Multicenter Glaucoma Study Investigating Standalone Canaloplasty

MAGIC
Start date: May 9, 2023
Phase: N/A
Study type: Interventional

A multicenter, randomized, clinical trial to evaluate the efficacy of canaloplasty performed as a standalone procedure using the iTrackā„¢ Advance canaloplasty device (Nova Eye, Inc.) as compared to the OMNI® Surgical System (Sight Sciences) in patients with mild to moderate primary open-angle glaucoma.

NCT ID: NCT05786131 Recruiting - Clinical trials for Multivessel Coronary Artery Disease

Complete Revascularization Versus Culprit Lesion Only PCI in NSTEMI

CompleteNSTEMI
Start date: October 27, 2023
Phase: N/A
Study type: Interventional

Prospective, randomized, controlled, multicenter, open-label trial to study whether multivessel percutaneous coronary intervention (PCI) is superior over culprit-lesion only PCI in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel coronary artery disease.

NCT ID: NCT05785624 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

Start date: May 26, 2023
Phase: Phase 2
Study type: Interventional

The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks.

NCT ID: NCT05784246 Recruiting - Ulcerative Colitis Clinical Trials

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

SHINE-2
Start date: November 22, 2023
Phase: Phase 3
Study type: Interventional

The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC).

NCT ID: NCT05782556 Recruiting - Liver Cirrhosis Clinical Trials

Freiburg TIPS Registry

FRETIR
Start date: January 1, 2023
Phase:
Study type: Observational [Patient Registry]

Patients with clinically significant portal hypertension allocated to implantation of a transjugular intrahepatic portosystemic shunt (TIPS) at the Department of Medicine II of the University Medical Center Freiburg, Germany will be offered to participate in this prospective observational trial. Clinical and laboratory as well as outcome parameters will be assessed before and within the first 12 months after TIPS implantation following a regular follow-up schedule with clinical visits at the University Medical Center Freiburg. During follow-up visits, serum/plasma samples and peripheral blood mononuclear cells (PBMC) are collected and stored in a associated biobank.

NCT ID: NCT05780736 Recruiting - Clinical trials for Esophageal Carcinoma

A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer

PROSPECT-ESO
Start date: August 4, 2023
Phase:
Study type: Observational

The purpose of this study is to describe the effectiveness and use of nivolumab after surgery in participants with early stage (Stage II/III) Esophageal Cancer/Gastroesophageal Junction Cancer (EC/GEJC).

NCT ID: NCT05780385 Recruiting - Critical Care Clinical Trials

Nasotracheal Intubation in Critically Ill.

NaTra-P
Start date: February 10, 2023
Phase: N/A
Study type: Interventional

The aim of this prospective randomized trail is to compare nasotracheal versus orotracheal intubation in critically ill patients. We aim to study: - required sedation depth - rate of spontaneous breathing - extend and possibility of physiotherapy - vasopressor and sedative drug doses Participants are randomized 1:1 to receive either nasotracheal or orotracheal intubation.

NCT ID: NCT05779202 Recruiting - Cardiomyopathies Clinical Trials

Observational Study on Cardiac Biomarkers Testing in Patients With Muscular Dystrophy Cardiomyopathy

KYMA
Start date: April 1, 2023
Phase:
Study type: Observational [Patient Registry]

The objective of this study is to evaluate acute changes of cardiac troponin (and other cardiac biomarkers) and mid-term biovariability in patients with cardiomyopathy associated with chronic skeletal muscle disease. The specific aims of the study are: Firstly, to evaluate the feasibility of the ESC 0/1 hour protocol for rule-in and rule-out of a non-ST-segment elevation acute coronary syndrome (NSTE-ACS). Secondly, a) to determine reference change values (RCV) to characterize physiological biovariability, b) to differentiate acute from chronic high-sensitivity cardiac troponin T (hs-cTnT) elevations.

NCT ID: NCT05778643 Recruiting - Clinical trials for Major Depressive Disorder

TaKeTiNa in the Treatment of Depression: a Pilot Study.

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical study's to analyse the impact of TaKeTiNa music therapy in depressed patients. The main question[s] it aims to answer are: . Can TaKeTiNa result in a significant pre-to-post intervention decline of depression severity 2. Can TaKeTiNa result in a significantly lower post-intervention depression severity in the T1/T2 group than in the W1/W2 group. Participants will - be randomly assigned to the two groups, intervention vs. waitlist - receive either an eight week TaKeTiNa music therapy or waitlist - be analysed using questionaires, blood taking, cortisol saliva analysis, measured heart rate variability Researchers will compare a waitlist to see if TakeTiNa is superior to waitlist